Abstract

Background. Concurrent chemoradiotherapy with cisplatin is the standard therapy for patients with unresectable locally advanced head and neck squamous cell carcinoma. However, cisplatin administration in patients on hemodialysis is complicated by the need to perform hemodialysis immediately after the infusion. Concurrent chemoradiation with cetuximab has been approved in definitive treatment of locally advanced head and neck cancer. Although cetuximab is not excreted via the kidneys, its use in patients on hemodialysis has not been reported. Methods and Results. We present the case of a 65-yearold man undergoing hemodialysis, with stage IVA squamous cell carcinoma of the hypopharynx. Given the logistics of performing hemodialysis immediately postcisplatin, he received concurrent chemoradiotherapy with cetuximab. He tolerated treatment well with minor side effects. Conclusion. Cetuximab can be safely used in patients with renal impairment. This is the first reported case of the use of cetuximab in a patient undergoing hemodialysis.

Original languageEnglish (US)
Pages (from-to)1647-1650
Number of pages4
JournalHead and Neck
Volume31
Issue number12
DOIs
StatePublished - Dec 1 2009

Fingerprint

Renal Dialysis
Chemoradiotherapy
Cisplatin
Kidney
Hypopharynx
Head and Neck Neoplasms
Cetuximab
Squamous Cell Carcinoma
Therapeutics

Keywords

  • Cetuximab
  • Chemoradiation
  • Head and neck cancer
  • Hemodialysis
  • Renal failure

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Cetuximab in hemodialysis : A case report. / Aldoss, Ibrahim T.; Plumb, Troy J; Zhen, Weining; Lydiatt, Daniel D.; Ganti, Apar Kishor P.

In: Head and Neck, Vol. 31, No. 12, 01.12.2009, p. 1647-1650.

Research output: Contribution to journalArticle

Aldoss, Ibrahim T. ; Plumb, Troy J ; Zhen, Weining ; Lydiatt, Daniel D. ; Ganti, Apar Kishor P. / Cetuximab in hemodialysis : A case report. In: Head and Neck. 2009 ; Vol. 31, No. 12. pp. 1647-1650.
@article{e0aa12cdf19c488c92452a63ff5489f4,
title = "Cetuximab in hemodialysis: A case report",
abstract = "Background. Concurrent chemoradiotherapy with cisplatin is the standard therapy for patients with unresectable locally advanced head and neck squamous cell carcinoma. However, cisplatin administration in patients on hemodialysis is complicated by the need to perform hemodialysis immediately after the infusion. Concurrent chemoradiation with cetuximab has been approved in definitive treatment of locally advanced head and neck cancer. Although cetuximab is not excreted via the kidneys, its use in patients on hemodialysis has not been reported. Methods and Results. We present the case of a 65-yearold man undergoing hemodialysis, with stage IVA squamous cell carcinoma of the hypopharynx. Given the logistics of performing hemodialysis immediately postcisplatin, he received concurrent chemoradiotherapy with cetuximab. He tolerated treatment well with minor side effects. Conclusion. Cetuximab can be safely used in patients with renal impairment. This is the first reported case of the use of cetuximab in a patient undergoing hemodialysis.",
keywords = "Cetuximab, Chemoradiation, Head and neck cancer, Hemodialysis, Renal failure",
author = "Aldoss, {Ibrahim T.} and Plumb, {Troy J} and Weining Zhen and Lydiatt, {Daniel D.} and Ganti, {Apar Kishor P}",
year = "2009",
month = "12",
day = "1",
doi = "10.1002/hed.21057",
language = "English (US)",
volume = "31",
pages = "1647--1650",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Cetuximab in hemodialysis

T2 - A case report

AU - Aldoss, Ibrahim T.

AU - Plumb, Troy J

AU - Zhen, Weining

AU - Lydiatt, Daniel D.

AU - Ganti, Apar Kishor P

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background. Concurrent chemoradiotherapy with cisplatin is the standard therapy for patients with unresectable locally advanced head and neck squamous cell carcinoma. However, cisplatin administration in patients on hemodialysis is complicated by the need to perform hemodialysis immediately after the infusion. Concurrent chemoradiation with cetuximab has been approved in definitive treatment of locally advanced head and neck cancer. Although cetuximab is not excreted via the kidneys, its use in patients on hemodialysis has not been reported. Methods and Results. We present the case of a 65-yearold man undergoing hemodialysis, with stage IVA squamous cell carcinoma of the hypopharynx. Given the logistics of performing hemodialysis immediately postcisplatin, he received concurrent chemoradiotherapy with cetuximab. He tolerated treatment well with minor side effects. Conclusion. Cetuximab can be safely used in patients with renal impairment. This is the first reported case of the use of cetuximab in a patient undergoing hemodialysis.

AB - Background. Concurrent chemoradiotherapy with cisplatin is the standard therapy for patients with unresectable locally advanced head and neck squamous cell carcinoma. However, cisplatin administration in patients on hemodialysis is complicated by the need to perform hemodialysis immediately after the infusion. Concurrent chemoradiation with cetuximab has been approved in definitive treatment of locally advanced head and neck cancer. Although cetuximab is not excreted via the kidneys, its use in patients on hemodialysis has not been reported. Methods and Results. We present the case of a 65-yearold man undergoing hemodialysis, with stage IVA squamous cell carcinoma of the hypopharynx. Given the logistics of performing hemodialysis immediately postcisplatin, he received concurrent chemoradiotherapy with cetuximab. He tolerated treatment well with minor side effects. Conclusion. Cetuximab can be safely used in patients with renal impairment. This is the first reported case of the use of cetuximab in a patient undergoing hemodialysis.

KW - Cetuximab

KW - Chemoradiation

KW - Head and neck cancer

KW - Hemodialysis

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=72449121397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449121397&partnerID=8YFLogxK

U2 - 10.1002/hed.21057

DO - 10.1002/hed.21057

M3 - Article

VL - 31

SP - 1647

EP - 1650

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 12

ER -